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Background: While the appearance of red clots in the dialyzer is a common phenomenon in every hemodialysis
unit, the occurrence of white thrombi in the tubing is relatively rare.
Case presentation: We describe an adolescent male with recurrent white thrombi formation in the hemodialysis
tubing. This patient had chronic renal failure from focal segmental glomerulosclerosis, but was no longer nephrotic
at the time of the thrombi formation. He had a history of recurrent thrombosis of his vascular access. However, no
pro-thrombotic risk factors could be identified. White particulate matter, measuring 1 to 3mm in size, and adherent
to the arterial and venous blood tubing lines was found during the rinse back of a hemodialysis session. This was
associated with a 60% decrease in his platelet count. Light microscopic examination of the deposits revealed the
presence of platelet aggregates. He subsequently developed thrombosis of his arteriovenous graft six hours later. The
white thrombi recurred at the next dialysis session, as well as six months later. These episodes occurred regardless of
the type of dialysis machine or tubing, and appeared to resolve with an increase in heparin dose.
Conclusion: Recurrent white thrombi formation can occur in the hemodialysis tubing of a patient with no identifiable
pro-thrombotic factors. The white thrombi may be a harbinger of arteriovenous graft thrombosis and may be prevented
by an increase in heparin dose.
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Surface interaction between artificial material and blood
during hemodialysis can lead to activation of comple-
ment, platelets as well as the coagulation cascade. The
dialyzer membrane is often thought to be the main cul-
prit in initiating these reactions, while the blood tubing
in the circuit is generally believed to be inert. Biocom-
patibility of artificial materials used in hemodialysis is
determined by the type of material, sterilisation mode
and geometry [1,2]. Poor biocompatibility can lead to
decreased platelet counts and abnormal platelet function
during dialysis [3], but acute thrombotic events are rare.* Correspondence: kar_hui_ng@nuhs.edu.sg
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unless otherwise stated.Here, we describe a case of recurrent white (platelet)
thrombi formation in the hemodialysis tubing of a patient
with no identifiable pro-thrombotic risk factors.
Case presentation
The patient is a 16-year old Indian male who presented
at the age of two years with nephrotic syndrome. This
did not respond to initial steroid treatment and renal bi-
opsy eventually revealed collapsing focal segmental glo-
merulosclerosis. No mutations in podocin and nephrin
genes were found. He responded to a combination treat-
ment regime comprising of prednisolone, cyclosporine A
and mycophenolate mofetil. After a course of rituximab
at the age of 14 years, he achieved remission and was
maintained without steroids or other immunosuppressive
therapy. Unfortunately, he relapsed one year later and
progressed quickly to end-stage renal failure when he
was 16 years old.
He was commenced on thrice-weekly conventional
hemodialysis, using Gambro® AK 95™, via a permanenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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coagulation. Platelet count remained normal during this
period. His residual renal function declined rapidly, and
three months after initiation of dialysis, he was no longer
nephrotic. A brachio-axillary arteriovenous graft (AVG)
was then created, but he developed four episodes of AVG
thrombosis over a period of four months, necessitating re-
peated thrombectomies and angioplasties. Clopidogrel
therapy did not prevent the recurrent thrombosis. Investi-
gations revealed persistently elevated serum homocysteine
level of 21.8 μmol/L (reference range 5 to 15 μmol/L)
despite normal folate and vitamin B12 levels. Protein
C, protein S, and antithrombin III levels were normal,
and he was negative for factor V Leiden and antiphospho-
lipid antibodies (anti-β2 glycoprotein, anti-cardiolipin anti-
bodies and lupus anticoagulant). He had no other
history of thrombotic events and the family history was
similarly non-contributory. He had never smoked and
was not obese (body mass index 20.4 kg/m2).
The patient switched to home hemodialysis, using the
NxStage® System One cycler, nine months after initiation
of renal replacement therapy. His dialysis prescription
was based on a target standard urea weekly Kt/V of 2.0
and involved five-hour sessions four times a week via his
permanent catheter. A single bolus of unfractionated
heparin 1,500 units was given at the beginning of each
session. The first three sessions were uneventful. At the
end of the fourth session, red clots were observed in the
dialyzer. Accordingly, the bolus heparin dose was in-
creased to 2,000 units at the following session. During
rinse back at the end of the fifth session, white particu-
late matter measuring 1 to 3mm was found firmly adher-
ent to the arterial and venous blood tubing (Figure 1).
These were not present in the drip chamber or dialysate
lines. Red clots were simultaneously noted in the dia-
lyzer. The patient remained clinically well before, duringFigure 1 White particulate matter measuring 1 to 3mm found adhereand immediately after dialysis. The access, effluent and
venous pressures during this session were not significantly
higher than previous sessions. He presented to our neph-
rology service six hours later when he noticed decreased
thrill in his AVG and was found to have AVG thrombosis,
necessitating thrombectomy and stenting. Subsequent
dialysis was carried out via conventional hemodialysis
using Gambro® AK 95™. Unfractionated heparin was
given at 1000 units and 500 units per hour as loading
and maintenance doses respectively. During rinse back
at the end of the next dialysis session, similar white par-
ticulate matter was again noted in the tubing, along with
red clots in the dialyzer.
Several investigations were performed to elicit the cause
of white particulate matter. Blood biochemistry and clot-
ting function were all within acceptable limits. There was
a 60% decrease in his platelet count (405 × 109/L) two
weeks prior; to 163 × 109/L on the first day of white
thrombi formation. At the second episode two days later,
the platelet count increased slightly to 199 × 109/L. His
hemoglobin level (11.2 g/dL) and leukocyte count (8.27 ×
109/L) remained stable from baseline. Complement levels
were normal. Antibodies for heparin-associated immune
thrombocytopenia (HIT) were not measured. Analysis of
the dialysate composition was within acceptable limits,
with absence of free chlorine, chloramine, heavy metals
and endotoxin. Dialysate microbiological cultures were
negative. The polyvinylchloride tubing with the white par-
ticulate matter was cut and light microscopic examination
of the deposits revealed platelet aggregates.
After the second episode of white thrombi formation,
he was switched back to NxStage® System One home
hemodialysis. An additional midway bolus of heparin
1,000 units was given for a few sessions with no further
recurrence of white thrombi. Unfortunately, NxStage®
home hemodialysis had to be discontinued after twont to the arterial and venous blood tubing lines after rinse back.
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peripheral nerve injuries sustained during the creation of
his AVG. During the 2 months of waiting for neurologic
recovery, he was placed on Gambro® AK 95™ conventional
hemodialysis with standard heparin doses. When he was
converted back to NxStage® home hemodialysis, he had a
newly created arteriovenous fistula. In an attempt to pre-
vent fistula thrombosis, the anticoagulation regimen was
changed to intravenous enoxaparin on dialysis days, and
subcutaneous enoxaparin on non-dialysis days. His peak
anti-Xa levels were maintained at 0.45 to 0.59 IU/ml on
dialysis days. A third episode of white thrombi formation
occurred while on NxStage® and the dose of enoxaparin
was increased with no further recurrence. None of the
other nine patients in the hemodialysis unit experienced
the same phenomenon throughout the entire period.
Conclusions
We report the repeated occurrence of white thrombi
formation in the hemodialysis tubing of an adolescent
male who probably had a pro-thrombotic tendency of
undetermined cause. While the appearance of red clots
in the dialyzer is a common phenomenon in every
hemodialysis unit, the occurrence of white thrombi in
the dialysis tubing is relatively rare. These episodes in
our patient occurred regardless of the type of dialysis
machine or tubing, and appeared to resolve with an in-
crease in heparin dose.
Reports on reactions to hemodialysis tubing lines are
scarce. In contrast, reactions to dialyzer membranes have
been widely described. Such reactions can cause transient
but significant intra-dialytic thrombocytopenia [3-5], and
appear to depend on the manufacturer, polyvinylpyrroli-
done content and sterilization method of the membrane
[3,6,7]. Postulated mechanisms include biochemical inter-
actions between blood and dialyzer membrane leading to
complement and platelet activation. Activated platelets
can form platelet-neutrophil, platelet-erythrocyte and
platelet-platelet aggregates during dialysis [3,8]. Despite
the formation of such aggregates, reactions to dialyzer
membranes do not generally lead to increased risk of
thrombosis.
In a previous report by Watnick et al., white thrombi
developed in the hemodialysis tubing of 21 out of 34
adult patients in a dialysis unit over a 5-week period
[9]. This phenomenon did not occur after switching to
dialysis lines from different manufacturers [9]. The
white thrombi, however, recurred immediately after re-
instatement of the dialysis lines from the original
manufacturer, suggesting that dialysis tubing irregular-
ities sustained during the manufacturing process could
be the precipitating cause of white thrombi. These tub-
ing defects could entrap microbubbles and enhance
thrombogenicity.In contrast, our patient was the only one who developed
recurrent white thrombi in our hemodialysis unit over the
7-month period, regardless of the type of hemodialysis
system (NxStage® and Gambro® systems). This supports
our conclusion that it was his pro-thrombotic state that
predisposed him to white thrombi formation, rather than
the properties of any particular dialysis tubing. Similarly,
in the series described by Watnick et al., a small subset of
patients had recurrent white matter deposits despite the
use of different machines on different occasions [9],
suggesting the presence of unidentified patient-specific
factors such as platelet function abnormalities.
The white thrombi formation described in our patient
was most likely related to platelet activation, in view of
the significant decrease in platelet count and the presence
of platelet aggregates on microscopic examination of
the white thrombi. We postulate that there was activation
of the coagulation cascade, resulting in generation of
thrombin which directly caused platelet activation and
aggregation, and ultimately AVG thrombosis. Chronic
renal failure is associated with changes in platelet function,
coagulation and fibrinolytic factors such as thrombin-
antithrombin III complex, fibrinopeptide A, D-dimer,
von Willebrand factor and beta-thromboglobulin, leading
to increased procoagulatory activity [10-13]. In addition,
there is release of thromboxane A2 and adenosine diphos-
phate into the circulation, as well as increased platelet de-
granulation and aggregation [10-12]. Uremic patients have
also been shown to have abnormalities in the platelet
glycoprotein GPIb (receptor for von Willebrand factor),
which were not corrected by hemodialysis or peritoneal
dialysis [13]. Moreover, sera from patients on hemodialysis
increased the expression of tissue factor in endothelial
cells or smooth muscle cells and enhanced the platelet
deposition in extracellular matrix [14,15].
The degree of hyperhomocysteinemia in our patient
was expected because of his renal failure [16,17]. Patients
on regular hemodialysis have higher serum homocysteine
levels than healthy controls [18], possibly due to decreased
homocysteine catabolism by the diseased kidneys [19].
Hyperhomocysteinemia is viewed as a non-traditional
marker for cardiovascular disease, as it is associated with
atherosclerotic events [18,20]. While it may be part of the
prothrombotic milieu in chronic renal failure [16,17], its
exact role in the thrombogenic process is not clear. Pos-
sible mechanisms include endothelial cell injury which
in turn stimulates the local coagulation system [16,21],
or activation of the coagulation cascade via increased
plasma tissue factor expression [22].
Our patient developed AVG thrombosis between the
first and second episodes of the white thrombi formation,
which occurred at consecutive dialysis sessions. While
there was no evidence that the AVG thrombosis was dir-
ectly caused by the white thrombi, it is conceivable that
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activation. The temporal association of his thrombocytopenia,
white clot formation and arterial thrombosis was reminis-
cent of HIT. Although HIT also involves platelet activation
(related to antibodies to heparin-platelet factor 4 (PF4)
complex), it was unlikely in our patient since the white
thrombi occurred nine months after continuous heparin
exposure, way beyond the time period when HIT typically
occurs (usually five to ten days after initiation of heparin
therapy [23]). For this reason, HIT antibody was not tested
in our patient.
An increase in heparin dose appeared to prevent the
recurrence of white thrombi in our patient. This was ex-
pected since heparin inactivates thrombin and therefore
inhibits thrombin-induced activation of platelets. Low
molecular weight heparins are probably as effective as
unfractionated heparin in preventing extracorporeal circuit
thrombosis [24].
In conclusion, this case highlights recurrent white
thrombi formation in a dialysis patient with probable
pro-thrombotic predisposition of undetermined cause.
Such an episode may be a harbinger of AVG thrombosis
and may be prevented by an increase in heparin dose.
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